Prostate Cancer
Research


Volume 7 Number 7
July 2019


Home > Disciplines > Publications > Prostate Cancer Research > Volume 7, Year 2019 > Number 7, July



CONTENTS


CASE REPORTS
DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, QUALITY OF LIFE
INTEGRATIVE MEDICINE
PROGNOSIS
TREATMENT



CASE REPORTS

.

Duncan C, Zamir E, Teh J, Joon DL, Liodakis P.
A blind spot in urology: Prostate cancer associated retinopathy.
Urol Case Rep. 2019 Mar 16;24:100872. doi: 10.1016/j.eucr.2019.100872. eCollection 2019 May.
Source | Full text | Similar articles



DIAGNOSIS

.

Afshar-Oromieh A, Vollnberg B, Alberts I, Bähler A, Sachpekidis C, Dijkstra L, Haupt F, Boxler S, Gross T, Holland-Letz T, Thalmann G, Heverhagen J, Rominger A, Härmä K, Maurer MH.
Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis.
Eur J Nucl Med Mol Imaging. 2019 Jul 27. doi: 10.1007/s00259-019-04438-w. [Epub ahead of print]
Source | Abstract | Similar articles



.

Chen M, Qiu X, Zhang Q, Zhang C, Zhou Y, Zhao X, Fu Y, Wang F, Guo H.
PSMA uptake on [68Ga]-PSMA-11-PET/CT positively corrects with prostate cancer aggressiveness.
Q J Nucl Med Mol Imaging. 2019 Jul 30. doi: 10.23736/S1824-4785.19.03172-8. [Epub ahead of print]
Source | Abstract | Similar articles



.

De Bari B, Mazzola R, Aiello D, Aloi D, Gatta R, Corradini S, Salgarello M, Alongi F.
(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy.
Cancer Radiother. 2019 Jun;23(3):194-200. doi: 10.1016/j.canrad.2018.09.003. Epub 2019 May 12.
Source | Full text | Similar articles



.

Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP.
68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
J Urol. 2019 Jun 24:101097JU0000000000000417. doi: 10.1097/JU.0000000000000417. [Epub ahead of print]
Source | Abstract | Similar articles



.

Favorito LA.
The multiparametric prostate resonance imaging with the prostate imaging-reporting and data system (PI-RADS): the state of art of prostate cancer diagnosis.
Int Braz J Urol. 2019 May-Jun;45(3):422-423. doi: 10.1590/S1677-5538.IBJU.2019.03.01.
Source | Full text | Similar articles
Editorial referring to: Rozas GQ, et al.,Impact of PI-RADS v2 on indication of prostate biopsy. Int Braz J Urol. 2019 May-Jun;45(3):486-494. doi: 10.1590/S1677-5538.IBJU.2018.0564. Source / Full text / Similar articles



.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
JAMA Oncol. 2019 Mar 28. doi: 10.1001/jamaoncol.2019.0096. [Epub ahead of print]
Source | Full text | Similar articles



.

Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, Trinh QD, Kibel AS.
Contemporary national trends in prostate cancer risk profile at diagnosis.
Prostate Cancer Prostatic Dis. 2019 Jun 24. doi: 10.1038/s41391-019-0157-y. [Epub ahead of print]
Source | Full text | Similar articles



.

Hadaschik B, Ost P.
Re: Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Eur Urol. 2019 May 23. pii: S0302-2838(19)30420-8. doi: 10.1016/j.eururo.2019.05.016. [Epub ahead of print]
Source | Full text | Similar articles



.

Kalapara AA, Nzenza T, Pan HY, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858. [Epub ahead of print]
Source | Full text | Similar articles



.

Koschel SG, Wong LM, Heinze S, Zargar H.
Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
Eur Urol. 2019 May 27. pii: S0302-2838(19)30424-5. doi: 10.1016/j.eururo.2019.05.020. [Epub ahead of print]
Source | Full text | Similar articles
Comment on: Johnson DC et al, Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30930-8. doi: 10.1016/j.eururo.2018.11.031. [Epub ahead of print] Source / Full text / Similar articles



.

Panebianco V, Valerio MC, Giuliani A, Pecoraro M, Ceravolo I, Barchetti G, Catalano C, Padhani AR.
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
Eur Urol Oncol. 2018 Aug;1(3):208-214. doi: 10.1016/j.euo.2018.03.008. Epub 2018 May 15.
Source | Full text | Similar articles



.

Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, Schiller K, Weber WA, Eiber M.
Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy.
J Nucl Med. 2019 Jun 28. pii: jnumed.119.229187. doi: 10.2967/jnumed.119.229187. [Epub ahead of print]
Source | Full text | Similar articles



.

Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA.
Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
J Nucl Med. 2019 Jun 14. pii: jnumed.119.226514. doi: 10.2967/jnumed.119.226514. [Epub ahead of print]
Source | Full text | Similar articles



.

Rozas GQ, Saad LS, Melo HJFE, Gabrielle HAA, Szejnfeld J.
Impact of PI-RADS v2 on indication of prostate biopsy.
Int Braz J Urol. 2019 May-Jun;45(3):486-494. doi: 10.1590/S1677-5538.IBJU.2018.0564.
Source | Full text | Similar articles



.

Tonttila PP, Ahtikoski A, Kuisma M, Pääkkö E, Hirvikoski P, Vaarala MH.
Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.
BJU Int. 2019 May 18. doi: 10.1111/bju.14812. [Epub ahead of print]
Source | Full text | Similar articles



.

Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
BJU Int. 2019 May 29. doi: 10.1111/bju.14828. [Epub ahead of print]
Source | Full text | Similar articles



.

Viana PCC, Horvat N, do Santos VR Júnior, Lima TC, Romão DDS, Cerri LMO, de Castro MG, Vargas HA, Miranda JA, Leite CDC, Cerri GG.
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Int Braz J Urol. 2019 May 5;45. doi: 10.1590/S1677-5538.IBJU.2018.0382. [Epub ahead of print]
Source | Full text | Similar articles



.

Wang B, Deng H, Cao L.
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
Eur Urol. 2019 May 17. pii: S0302-2838(19)30377-X. doi: 10.1016/j.eururo.2019.05.004. [Epub ahead of print]
Source | Full text | Similar articles
Referring to: Ahmadzadehfar H, Essler M. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. 2019 Mar 2. pii: S0302-2838(19)30175-7. doi: 10.1016/j.eururo.2019.02.028. [Epub ahead of print] Source / Full text / Similar articles
In turn Referring to: Perera M et al., Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095-8. doi: 10.1016/j.eururo.2019.01.049. [Epub ahead of print]. Source / Full text



.

Westphalen AC, Fazel F, Nguyen H, Cabarrus M, Hanley-Knutson K, Shinohara K, Carroll PR.
Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
Int Braz J Urol. 2019 May 5;45. doi: 10.1590/S1677-5538.IBJU.2018.0768. [Epub ahead of print]
Source | Full text | Similar articles



.

Zacho H, Jochumsen MR, Langkilde NC, Mortensen JC, Haarmark C, Hendel HW, Jensen JB, Petersen LJ.
No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy.
J Nucl Med. 2019 May 30. pii: jnumed.119.229062. doi: 10.2967/jnumed.119.229062. [Epub ahead of print]
Source | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Abdel-Rahman O.
Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial.
Clin Genitourin Cancer. 2019 May 25. pii: S1558-7673(19)30153-3. doi: 10.1016/j.clgc.2019.05.015. [Epub ahead of print]
Source | Full text | Similar articles



.

Bonn SE, Holmberg E, Hugosson J, Bälter K.
Is leisure time sitting associated with mortality rates among men diagnosed with localized prostate cancer?
Eur J Cancer Prev. 2019 Jul 22. doi: 10.1097/CEJ.0000000000000523. [Epub ahead of print]
Source | Abstract | Similar articles



.

Liss MA, Al-Bayati O, Gelfond J, Goros M, Ullevig S, DiGiovanni J, Hamilton-Reeves J, O'Keefe D, Bacich D, Weaver B, Leach R, Thompson IM.
Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.
Prostate Cancer Prostatic Dis. 2019 May;22(2):244-251. doi: 10.1038/s41391-018-0105-2. Epub 2018 Nov 1.
Source | Full text | Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY

.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.
Source | Full text | Similar articles



.

Ma X, Huang J.
Predicting clinical outcome of therapy-resistant prostate cancer.
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11090-11092. doi: 10.1073/pnas.1906812116. Epub 2019 May 21.
Source | Full text | Similar articles
Comment on: Abida W, et al, Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.
Source / Full text / Similar articles



.

Mauffrey P, Tchitchek N, Barroca V, Bemelmans A, Firlej V, Allory Y, Roméo PH, Magnon C.
Progenitors from the central nervous system drive neurogenesis in cancer.
Nature. 2019 May;569(7758):672-678. doi: 10.1038/s41586-019-1219-y. Epub 2019 May 15.
Source | Full text | Similar articles



.

Zadra G, Loda M.
When fat goes down, prostate cancer is on the ropes.
Mol Cell Oncol. 2019 Apr 16;6(3):1595308. doi: 10.1080/23723556.2019.1595308. eCollection 2019.
Source | Full text | Similar articles



FOLLOW-UP, QUALITY OF LIFE

.

Albisinni S, Aoun F, Quackels T, Assenmacher G, Peltier A, van Velthoven R, Roumeguère T.
Validated Prospective Assessment of Quality of Life After Robot-Assisted Laparoscopic Prostatectomy: Beyond Continence and Erections.
Am J Mens Health. 2019 May-Jun;13(3):1557988319854555. doi: 10.1177/1557988319854555.
Source | Full text | Similar articles



.

Chung JW, Kim JW, Ha YS, Choi SH, Lee JN, Kim BS, Kim HT, Yoo ES, Kwon TG, Kim TH.
The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Urol J. 2019 Jun 17;16(3):255-259. doi: 10.22037/uj.v16i3.4263.
Source | Full text | Similar articles



.

Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ.
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
JAMA Netw Open. 2019 Jul 3;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562.
Source | Full text | Similar articles



.

Leufgens F, Berneking V, Vögeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M.
Quality of life changes >10 years following postoperative radiotherapy after radical prostatectomy for prostate cancer.
Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30829-6. doi: 10.1016/j.ijrobp.2019.06.004. [Epub ahead of print]
Source | Abstract | Similar articles



.

Neumaier MF, Segall CH Júnior, Hisano M, Rocha FET, Arap S, Arap MA.
Factors affecting urinary continence and sexual potency recovery after robotic-assisted radical prostatectomy.
Int Braz J Urol. 2019 May 5;45. doi: 10.1590/S1677-5538.IBJU.2018.0704. [Epub ahead of print]
Source | Full text | Similar articles



INTEGRATIVE MEDICINE

.

Joentausta RM, Murtola TJ.
Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
Prostate. 2019 Sep;79(12):1420-1421. doi: 10.1002/pros.23870. Epub 2019 Jun 24.
Source | Full text | Similar articles
Comment on: Kawada T. RE: Joentausta et al. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591. Prostate. 2019 Sep;79(12):1399. doi: 10.1002/pros.23862. Epub 2019 Jul 23. Source / Full text / Similar articles
In turn Comment on: Joentausta RM, et al, Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16. Source / Full text / Similar articles



.

Joentausta RM, Rannikko A, Murtola TJ.
Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16.
Source | Full text | Similar articles



.

Kawada T.
RE: Joentausta et al. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
Prostate. 2019 Sep;79(12):1399. doi: 10.1002/pros.23862. Epub 2019 Jul 23.
Source | Full text | Similar articles
Comment on: Joentausta RM, et al, Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16. Source / Full text / Similar articles



.

Meijer D, van Moorselaar RJA, Vis AN, Bijnsdorp IV.
Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels.
Cancers (Basel). 2019 Jul 7;11(7). pii: E953. doi: 10.3390/cancers11070953.
Source | Full text | Similar articles



PROGNOSIS

.

Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V.
Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Cancer. 2019 May 31. doi: 10.1002/cncr.32202. [Epub ahead of print]
Source | Full text | Similar articles



.

Harkin T, Elhage O, Chandra A, Khan N, Kiberu Y, Frydenberg M, Dasgupta P.
High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma.
BJU Int. 2019 May 28. doi: 10.1111/bju.14831. [Epub ahead of print]
Source | Full text | Similar articles



.

Hernández Hernández C, Kim Lee D, Sanchez Pérez M, Escobar SH.
Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
Clin Genitourin Cancer. 2019 Jun;17(3):e645-e649. doi: 10.1016/j.clgc.2019.03.014. Epub 2019 Mar 27.
Source | Full text | Similar articles



.

Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, Sprenkle PC.
Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30148-8. doi: 10.1016/j.euf.2019.05.011. [Epub ahead of print]
Source | Full text | Similar articles



.

Koskas Y, Lannes F, Branger N, Giusiano S, Guibert N, Pignot G, Walz J, Rossi D, Bastide C.
Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up.
BMC Urol. 2019 May 15;19(1):37. doi: 10.1186/s12894-019-0470-8.
Source | Full text | Similar articles



.

Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).
Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
Eur Urol Oncol. 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002. Epub 2018 Dec 24.
Source | Abstract | Similar articles



.

Roy S, Morgan SC.
Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database.
Clin Oncol (R Coll Radiol). 2019 May 23. pii: S0936-6555(19)30191-8. doi: 10.1016/j.clon.2019.04.012. [Epub ahead of print]
Source | Full text | Similar articles



.

Sebastian NT, McElroy JP, Martin DD, Sundi D, Diaz DA.
Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
Urol Oncol. 2019 May 18. pii: S1078-1439(19)30155-3. doi: 10.1016/j.urolonc.2019.04.022. [Epub ahead of print]
Source | Full text | Similar articles



.

Seddik S, Silva M, Dugué AE, Ait Said K, Joly F, Tillou X.
Oncologic Outcomes of Adjuvant versus Salvage Radiotherapy after Prostatectomy.
Urol Int. 2019 Jun 21:1-7. doi: 10.1159/000501086. [Epub ahead of print]
Source | Abstract | Similar articles



.

Takeda T, Benfante NE, Assel M, Mulhall JP, Oya M, Touijer KA.
Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
Int J Urol. 2019 Jun 25. doi: 10.1111/iju.14043. [Epub ahead of print]
Source | Citation | Similar articles



TREATMENT

.

Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C.
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.
Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509. [Epub ahead of print]
Source | Full text | Similar articles



.

Cao HM, Wan Z, Wu Y, Wang HY, Guan C.
Development and internal validation of a novel model and markers to identify the candidates for lymph node metastasis in patients with prostate cancer.
Medicine (Baltimore). 2019 Jul;98(30):e16534. doi: 10.1097/MD.0000000000016534.
Source | Full text | Similar articles



.

Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U.
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Lancet Oncol. 2019 May;20(5):e228. doi: 10.1016/S1470-2045(19)30226-8.
Source | Full text | Similar articles
Comment on: Smith M et al, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. Source / Full text / Similar articles



.

Dirix PR, Mercier C, Dirix LY.
Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
Eur Urol. 2019 Jun 26. pii: S0302-2838(19)30507-X. doi: 10.1016/j.eururo.2019.06.022. [Epub ahead of print]
Source | Full text | Similar articles
Comment on: Lohaus F, et al., Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol. 2019 Apr;75(4):548-551. doi: 10.1016/j.eururo.2018.11.050. Epub 2018 Dec 18. Source / Full text / Similar articles



.

Gupta A, Pugh TJ, Lam E, Sheridan AD, Nath S.
The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer.
Oncology (Williston Park). 2019 May 14;33(5):187-91.
Source | Full text | Similar articles



.

Hindié E, Morgat C.
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Lancet Oncol. 2019 May;20(5):e229. doi: 10.1016/S1470-2045(19)30235-9.
Source | Full text | Similar articles
Comment on: Smith M et al, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. Source / Full text / Similar articles



.

Hölscher T, Lohaus F, Wirth M, Troost EGC.
Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30506-8. doi: 10.1016/j.eururo.2019.06.021. [Epub ahead of print]
Source | Full text | Similar articles
Comment on: Dirix PR, et al.,Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51. Eur Urol. 2019 Jun 26. pii: S0302-2838(19)30507-X. doi: 10.1016/j.eururo.2019.06.022. [Epub ahead of print] Source / Full text / Similar articles
In turn Comment on: Lohaus F, et al., Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol. 2019 Apr;75(4):548-551. doi: 10.1016/j.eururo.2018.11.050. Epub 2018 Dec 18. Source / Full text / Similar articles



.

Lan T, Chen Y, Su Q, Ye J.
Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases.
Urology. 2019 Jun 7. pii: S0090-4295(19)30507-2. doi: 10.1016/j.urology.2019.03.040. [Epub ahead of print]
Source | Full text | Similar articles



.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ.
Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
World J Urol. 2019 Jul 25. doi: 10.1007/s00345-019-02873-w. [Epub ahead of print]
Source | Full text | Similar articles



.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
Source | Full text | Similar articles



.

Song WH, Park JH, Tae BS, Kim SM, Hur M, Seo JH, Ku JH, Kwak C, Kim HH, Kim K, Jeong CW.
Establishment of Novel Intraoperative Monitoring and Mapping Method for the Cavernous Nerve During Robot-assisted Radical Prostatectomy: Results of the Phase I/II, First-in-human, Feasibility Study.
Eur Urol. 2019 May 15. pii: S0302-2838(19)30359-8. doi: 10.1016/j.eururo.2019.04.042. [Epub ahead of print]
Source | Full text | Similar articles



.

Spratt DE.
Combination therapies in prostate cancer: proceed with caution.
Lancet Oncol. 2019 Mar;20(3):321-323. doi: 10.1016/S1470-2045(18)30929-X. Epub 2019 Feb 6.
Source | Full text | Similar articles
Comment on: Smith M et al, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. Source / Full text / Similar articles



.

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.
Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
Clin Genitourin Cancer. 2019 May 24. pii: S1558-7673(18)30729-8. doi: 10.1016/j.clgc.2019.05.007. [Epub ahead of print]
Source | Full text | Similar articles



.

Thomsen FB, Røder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Brasso K.
Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Clin Genitourin Cancer. 2019 Aug;17(4):e814-e821. doi: 10.1016/j.clgc.2019.05.005. Epub 2019 May 21.
Source | Full text | Similar articles



.

Verep S, Erdem S, Ozluk Y, Kilicaslan I, Sanli O, Ozcan F.
The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Prostate. 2019 Jul 3. doi: 10.1002/pros.23873. [Epub ahead of print]
Source | Full text | Similar articles



bottom

***